Physician profile
Jonathan D Lopez
NPI 1881682714
$1,502.24
in general payments reported to CMS, 2019-2025
20 companies · $296 in 2025
The $296 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2021: $106 · 2022: $133 · 2023: $483 · 2024: $211 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958 · Education: $31.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.20 |
| Education | $31.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $194.80 | 2019-2025 | |
| Merz North America, INC. | $188.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $167.99 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $156.48 | 2019-2024 | Keytruda, Lynparza |
| Lilly USA, LLC | $113.47 | 2021-2024 | Jaypirca |
| Daiichi Sankyo INC. | $80.90 | 2023-2025 | Enhertu, Datroway |
| Amgen INC. | $73.62 | 2022-2023 | Lumakras |
| Celgene Corporation | $65.45 | 2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $62.32 | 2019-2024 | Iclusig |
| Eisai INC. | $62.10 | 2023-2024 | |
| Genentech USA, INC. | $52.81 | 2023-2025 | Venclexta, Phesgo |
| Array Biopharma INC | $47.85 | 2023-2025 | Braftovi, Mektovi, Tukysa |
| E.R. Squibb & Sons, L.L.C. | $41.34 | 2023-2024 | Opdualag, Opdivo |
| Astellas Pharma US INC | $39.39 | 2024-2025 | Padcev, Vyloy |
| Bayer Healthcare Pharmaceuticals INC. | $34.85 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $34.71 | 2021-2025 | Trodelvy |
| Janssen Biotech, INC. | $24.75 | 2023 | Imbruvica, Rybrevant |
| Abbvie INC. | $21.05 | 2025 | |
| Genzyme Corporation | $20.39 | 2019 | |
| Exelixis INC. | $19.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.